BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

Betsy Goodfellow | September 28, 2023 | News story | Research and Development AMR, BactiVac, Immunology, vaccines 

The University of Birmingham hosted Bacterial Vaccines Network has been awarded £1.4m in funding from the UK government to accelerate the development of bacterial vaccines in the fight against antimicrobial resistance (AMR). This funding follows the Global AMR Innovation Fund’s (GAMRIF) £1.4m award in 2019 – both of which are part of the UK’s five-year (2019-2024) AMR national action plan.

In January 2022, the Global burden of bacterial antimicrobial resistance was published, the research of which revealed that AMR is now a leading global cause of death after the five million deaths associated with bacterial AMR in 2019. This second phase of funding will allow BactiVac to continue their pipeline of vaccine development projects.

Professor Adam Cunningham, co-director of BactiVac, professor of Functional Immunity, commented: “GAMRIF supports strategies to tackle AMR and bacterial vaccines play a key role in this by preventing bacterial diseases from developing, removing the need to use antimicrobials and reduce opportunities for AMR to develop. This is a key reason why the partnership between GAMRIF and BactiVac is so important for controlling AMR.”

Professor Calman MacLennan, director of BactiVac, added: “We are extremely grateful to be partnering with GAMRIF. There is a clear synergy between our organisations and the support provided by GAMRIF is vital for delivering BactiVac’s objective of advancing vaccines against bacterial pathogens and AMR.”            

Daria da Silva

Related Content

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …


Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

GSK and Save the Children extend partnership for unvaccinated children

GSK and Save the Children have announced that they will be renewing their partnership for …

Latest content